Tearsheet
Investment Highlights Market Valuation Price Chart About DGX Interactive Breakdown Better Bets vs. DGX Latest Trefis Analyses Trade Ideas Recent Active Movers More From Trefis Peer Financials Peer Growth & Margins Peer Valuation Peer Returns Peer Analyses FDIC Bank Data Financials Segment Financials Price Behavior Short Interest Earnings Returns History SEC Filings Insider Activity Industry Resource Links External Quote Links

Quest Diagnostics (DGX)

Market Price (10/14/2025): $182.82 | Market Cap: $20.5 Bil
Sector: Health Care | Industry: Health Care Services

Quest Diagnostics (DGX)

Market Price (10/14/2025): $182.82
Market Cap: $20.5 Bil
Sector: Health Care
Industry: Health Care Services

Investment Highlights

0 Attractive yield
Total YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 6.3%, FCF Yield is 6.0%		 Trading close to highs
Dist 52W High is -3.7%, Dist 3Y High is -3.7%		 Weak revenue growth
Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is 0.2%
1 Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 16%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 12%		 Weak multi-year price returns
2Y Excs Rtn is -1.1%, 3Y Excs Rtn is -24%		 
2 Low stock price volatility
Vol 12M is 23%		  
0 Attractive yield
Total YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 6.3%, FCF Yield is 6.0%
1 Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 16%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 12%
2 Low stock price volatility
Vol 12M is 23%
3 Trading close to highs
Dist 52W High is -3.7%, Dist 3Y High is -3.7%
4 Weak multi-year price returns
2Y Excs Rtn is -1.1%, 3Y Excs Rtn is -24%
5 Weak revenue growth
Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is 0.2%

Market Valuation & Key Metrics

DGXS&P 500
REVENUE GROWTHFAIR
Rev LTM ($ Bil)10.5
Rev Chg Q15.2%6.1%
Rev Chg LTM12.6%5.2%
Rev Chg 3Y Avg0.2%5.3%
PROFITABILITYFAIR
Op Inc LTM ($ Bil)1.5
Op Mgn LTM14.0%18.6%
CFO LTM ($ Bil)1.7
CFO/Rev LTM15.9%20.3%
Net Inc LTM ($ Bil)0.9
Net Inc Mgn9.0%12.7%
VALUATIONMODERATE
P/S1.93.2
P/CFO12.215.6
P/FCF16.720.6
P/E21.623.6
STABILITYFAIR
Debt/Equity0.310.21
Cash/Assets0.020.07

DGX Stock

Factor Drivers of Stock Movement
The 9.8% change in DGX stock from 4/14/2025 to 10/13/2025 was primarily driven by a 6.6% change in the company's Total Revenues ($ Mil).

414202510132025Change
Stock Price ($)166.50182.789.78%
Change Contribution ByLTMLTM
Total Revenues ($ Mil)9872.0010522.006.58%
Net Income Margin (%)8.82%9.03%2.33%
P/E Multiple21.2221.551.56%
Shares Outstanding (Mil)111.00112.00-0.90%
Cumulative Contribution9.77%

LTM = Last Twelve Months as of date shown
The 25.3% change in DGX stock from 10/13/2024 to 10/13/2025 was primarily driven by a 12.6% change in the company's Total Revenues ($ Mil).

1013202410132025Change
Stock Price ($)145.91182.7825.27%
Change Contribution ByLTMLTM
Total Revenues ($ Mil)9346.0010522.0012.58%
Net Income Margin (%)8.99%9.03%0.46%
P/E Multiple19.2821.5511.76%
Shares Outstanding (Mil)111.00112.00-0.90%
Cumulative Contribution25.26%

LTM = Last Twelve Months as of date shown
The 54.0% change in DGX stock from 10/14/2022 to 10/13/2025 was primarily driven by a 130.2% change in the company's P/E Multiple.

1014202210132025Change
Stock Price ($)118.72182.7853.96%
Change Contribution ByLTMLTM
Total Revenues ($ Mil)10582.0010522.00-0.57%
Net Income Margin (%)14.02%9.03%-35.62%
P/E Multiple9.3621.55130.22%
Shares Outstanding (Mil)117.00112.004.27%
Cumulative Contribution53.68%

LTM = Last Twelve Months as of date shown

Price Returns Compared

 202020212022202320242025Total [1]
Returns
DGX Return14%48%-8%-10%12%23%94%
Peers Return38%16%-30%24%21%-6%58%
S&P 500 Return16%27%-19%24%23%13%103%

Monthly Win Rates [3]
DGX Win Rate58%75%50%42%58%67% 
Peers Win Rate60%58%38%50%55%47% 
S&P 500 Win Rate58%75%42%67%75%67% 

Max Drawdowns [4]
DGX Max Drawdown-31%-3%-29%-22%-10%0% 
Peers Max Drawdown-37%-15%-44%-8%-7%-27% 
S&P 500 Max Drawdown-31%-1%-25%-1%-2%-15% 

[1] Cumulative total returns since the beginning of 2020
[2] Peers: HCA, LH, DVA, SEM, NEO. See DGX Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 10/13/2025 (YTD)

Downturns Compared

Unique KeyEventDGXS&P 500
2022 Inflation Shock2022 Inflation Shock  
2022 Inflation Shock% Loss% Loss-29.6%-25.4%
2022 Inflation Shock% Gain to Breakeven% Gain to Breakeven42.1%34.1%
2022 Inflation ShockTime to BreakevenTime to Breakeven887 days464 days
2020 Covid Pandemic2020 Covid Pandemic  
2020 Covid Pandemic% Loss% Loss-36.6%-33.9%
2020 Covid Pandemic% Gain to Breakeven% Gain to Breakeven57.7%51.3%
2020 Covid PandemicTime to BreakevenTime to Breakeven24 days148 days
2018 Correction2018 Correction  
2018 Correction% Loss% Loss-30.6%-19.8%
2018 Correction% Gain to Breakeven% Gain to Breakeven44.2%24.7%
2018 CorrectionTime to BreakevenTime to Breakeven436 days120 days
2008 Global Financial Crisis2008 Global Financial Crisis  
2008 Global Financial Crisis% Loss% Loss-31.0%-56.8%
2008 Global Financial Crisis% Gain to Breakeven% Gain to Breakeven44.8%131.3%
2008 Global Financial CrisisTime to BreakevenTime to Breakeven388 days1480 days


How Low Can It Go?

Quest Diagnostics's stock fell -29.6% during the 2022 Inflation Shock from a high on 12/31/2021. A -29.6% loss requires a 42.1% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth over time.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Quest Diagnostics (DGX)

Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.

Better Bets than Quest Diagnostics (DGX)

 DGXBetter Performance than DGX
MetricValueIndustry (Health Care Services)
Rev Chg LTM12.6%CI (24.6%), HIMS (88.7%), VCYT (19.9%), ADUS (14.3%), SDGR (18.6%)
Rev Chg 3Y Avg0.2%CVS (8.1%), CI (13.2%), LH (4.2%), HIMS (76.3%), DVA (4.2%)
Op Mgn LTM14.0%DVA (15.0%), CHE (15.7%), SHC (27.8%), CON (15.7%)
CFO/Rev LTM15.9%SHC (23.7%), VCYT (19.5%), PINC (39.6%), PGNY (16.3%)
FCF/Rev LTM11.6%CHE (12.7%), VCYT (17.5%), PINC (31.5%), PGNY (15.3%), MD (11.7%)
Total Yield6.3%CVS (8.7%), CI (8.3%), DVA (8.9%), CON (66.4%), MD (8.1%)
 DGXBetter Performance than DGX
MetricValueAll Other Sectors
Rev Chg LTM12.6%NVDA (71.6%), MSFT (14.9%), GOOGL (13.1%), META (19.4%), AVGO (28.0%)
Rev Chg 3Y Avg0.2%NVDA (92.0%), MSFT (12.5%), AAPL (1.8%), GOOGL (10.2%), AMZN (11.3%)
Op Mgn LTM14.0%NVDA (58.1%), MSFT (45.6%), AAPL (31.9%), GOOGL (32.7%), META (42.9%)
CFO/Rev LTM15.9%NVDA (46.6%), MSFT (48.3%), AAPL (26.6%), GOOGL (36.0%), AMZN (18.1%)
FCF/Rev LTM11.6%NVDA (43.6%), MSFT (25.4%), AAPL (23.5%), GOOGL (18.0%), META (30.7%)
Total Yield6.3%JPM (6.6%), XOM (9.9%), BABA (37.8%), BAC (7.4%), KO (7.2%)

Latest Trefis Analyses

TitleTopicDate
0DASHBOARDS  
1Quest Diagnostics Earnings Notes  
2Quest Diagnostics vs Southern: Which Is A Better Investment?Counter-Intuitive Comparisons 
3Quest Diagnostics vs United Therapeutics: Which Is A Better Investment?Counter-Intuitive Comparisons 
4How Does Quest Diagnostics Stock Stack Up Against Its Peers?Peer Comparison 
5Better Bet Than DGX Stock: Pay Less Than Quest Diagnostics To Get More From SCCO, OKE   
6Better Bet Than DGX Stock: Pay Less Than Quest Diagnostics To Get More From UTHR, HALO   
7DGX Dip Buy Analysis  
8DGX YTD Stock Return Of 18% Outperforms NEO by 71% and Underperforms HCA by -11%Return 
9Quest Diagnostics vs. Out Of Favor Health Care Stocks: Which Is A Better Investment?Investment Theme Comparisons 
10Quest Diagnostics Total Shareholder Return (TSR): 13.4% in 2024 and -0.6% 3-yr compounded annual returns (above peer average)  
11ARTICLES  
12Will Quest Diagnostics Stock Rebound After A Large 19% Fall In A Month? January 19th, 2022
Title
0DASHBOARDS
1Will Quest Diagnostics Stock Rebound After A Large 19% Fall In A Month?
2ARTICLES
3Quest Diagnostics Earnings Notes
4Quest Diagnostics vs Southern: Which Is A Better Investment?
5Quest Diagnostics vs United Therapeutics: Which Is A Better Investment?
6How Does Quest Diagnostics Stock Stack Up Against Its Peers?
7Better Bet Than DGX Stock: Pay Less Than Quest Diagnostics To Get More From SCCO, OKE 
8Better Bet Than DGX Stock: Pay Less Than Quest Diagnostics To Get More From UTHR, HALO 
9DGX Dip Buy Analysis
10DGX YTD Stock Return Of 18% Outperforms NEO by 71% and Underperforms HCA by -11%
11Quest Diagnostics vs. Out Of Favor Health Care Stocks: Which Is A Better Investment?
12Quest Diagnostics Total Shareholder Return (TSR): 13.4% in 2024 and -0.6% 3-yr compounded annual returns (above peer average)

Trade Ideas

Select past trade ideas related to DGX and Health Care Services.

Unique KeyDateTickerCompanyCategoryTrade Strategy6M Fwd Rtn12M Fwd Rtn12M Max DD
ADMA_9302025_Dip_Buyer_ValueBuy09302025ADMAADMA BiologicsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		-0.8%-0.8%-4.6%
REGN_9302025_Dip_Buyer_ValueBuy09302025REGNRegeneron PharmaceuticalsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		0.4%0.4%0.0%
HAE_9262025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG09262025HAEHaemoneticsDip BuyDB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap		1.4%1.4%-0.1%
WAT_9192025_Monopoly_xInd_xCD_Getting_Cheaper09192025WATWatersMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		10.0%10.0%-4.3%
ISRG_9052025_Monopoly_xInd_xCD_Getting_Cheaper09052025ISRGIntuitive SurgicalMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		-8.0%-8.0%-8.0%
DGX_3312020_Dip_Buyer_ValueBuy03312020DGXQuest DiagnosticsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		43.3%63.4%-8.7%
Unique KeyDateTickerCompanyCategoryTrade Strategy6M Fwd Rtn12M Fwd Rtn12M Max DD
ADMA_9302025_Dip_Buyer_ValueBuy09302025ADMAADMA BiologicsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		-0.8%-0.8%-4.6%
REGN_9302025_Dip_Buyer_ValueBuy09302025REGNRegeneron PharmaceuticalsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		0.4%0.4%0.0%
HAE_9262025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG09262025HAEHaemoneticsDip BuyDB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap		1.4%1.4%-0.1%
WAT_9192025_Monopoly_xInd_xCD_Getting_Cheaper09192025WATWatersMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		10.0%10.0%-4.3%
ISRG_9052025_Monopoly_xInd_xCD_Getting_Cheaper09052025ISRGIntuitive SurgicalMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		-8.0%-8.0%-8.0%
DGX_3312020_Dip_Buyer_ValueBuy03312020DGXQuest DiagnosticsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		43.3%63.4%-8.7%

See Trefis Trade Ideas for more.

Recent Active Movers

1 Week Top Gainers

#TickerCompany1W RtnYTD Rtn
1UAMYUnited States Antimony106.6%844.1%
2BITFBitfarms55.8%261.7%
3ASPIASP Isotopes48.5%194.0%
4USARUSA Rare Earth47.0%129698.7%
5UUUUEnergy Fuels40.6%363.4%
6TMCTMC The Metals38.5%854.5%
7SESSES AI37.9%53.0%
8GLUEMonte Rosa Therapeutics35.8%49.9%
9APGEApogee Therapeutics35.5%19.1%
10METCRamaco Resources34.7%418.5%

1 Week Top Losers

#TickerCompany1W RtnYTD Rtn
1VGVenture Global-35.2% 
2BNBrookfield-34.2%17.5%
3BNTBrookfield Wealth Solutions-34.1%17.5%
4BBBYBed Bath & Beyond-28.6% 
5HELEHelen Of Troy-25.9%-67.4%
6PENGPenguin Solutions-23.8%16.3%
7USNAUsana Health Sciences-22.8%-42.8%
8TASKTaskUs-22.4%-21.8%
9NFENew Fortress Energy-21.8%-87.4%
10OPENOpendoor Technologies-21.7%354.4%

1 Month Top Gainers

#TickerCompany1M RtnYTD Rtn
1WOLFWolfspeed1297.9%389.0%
2QUREuniQure276.2%251.2%
3UAMYUnited States Antimony238.9%844.1%
4LACLithium Americas194.8%183.8%
5RGTIRigetti Computing187.6%259.8%
6USARUSA Rare Earth175.1%129698.7%
7SESSES AI168.0%53.0%
8PLUGPlug Power156.6%83.1%
9CLPTClearPoint Neuro150.4%70.8%
10BITFBitfarms141.7%261.7%

1 Month Top Losers

#TickerCompany1M RtnYTD Rtn
1ANGXAngel Studios-49.7% 
2REXREX American Resources-47.9%52.0%
3VGVenture Global-33.4% 
4USNAUsana Health Sciences-32.7%-42.8%
5FLYFirefly Aerospace-31.7% 
6LDIloanDepot-31.4%43.6%
7TIPTTiptree-29.9%-13.6%
8GOSSGossamer Bio-29.5%169.7%
9PGYPagaya Technologies-29.5%201.1%
10IDTIDT-29.4%-1.3%

Recent Active Movers

1 Week Top Gainers

#TickerCompany1W RtnYTD Rtn
1UAMYUnited States Antimony106.6%844.1%
2BITFBitfarms55.8%261.7%
3ASPIASP Isotopes48.5%194.0%
4USARUSA Rare Earth47.0%129698.7%
5UUUUEnergy Fuels40.6%363.4%
6TMCTMC The Metals38.5%854.5%
7SESSES AI37.9%53.0%
8GLUEMonte Rosa Therapeutics35.8%49.9%
9APGEApogee Therapeutics35.5%19.1%
10METCRamaco Resources34.7%418.5%

1 Week Top Losers

#TickerCompany1W RtnYTD Rtn
1VGVenture Global-35.2% 
2BNBrookfield-34.2%17.5%
3BNTBrookfield Wealth Solutions-34.1%17.5%
4BBBYBed Bath & Beyond-28.6% 
5HELEHelen Of Troy-25.9%-67.4%
6PENGPenguin Solutions-23.8%16.3%
7USNAUsana Health Sciences-22.8%-42.8%
8TASKTaskUs-22.4%-21.8%
9NFENew Fortress Energy-21.8%-87.4%
10OPENOpendoor Technologies-21.7%354.4%

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons for Quest Diagnostics

Financials

DGXHCALHDVASEMNEOMedian
NameQuest Di.HCA Heal.Labcorp DaVita Select M.NeoGenom. 
Mkt Price182.78410.68276.64123.9113.199.34153.34
Mkt Cap20.598.223.19.41.61.214.9
Rev LTM10,52272,69813,48413,1614,33168911,842
Op Inc LTM1,47511,0781,2341,976116-921,354
FCF LTM1,2247,2921,2621,288182-191,243
FCF 3Y Avg9925,7041,0841,305216-381,038
CFO LTM1,67811,9351,6941,862413141,686
CFO 3Y Avg1,43310,4511,5271,880438-71,480

Growth & Margins

DGXHCALHDVASEMNEOMedian
NameQuest Di.HCA Heal.Labcorp DaVita Select M.NeoGenom. 
Rev Chg LTM12.6%6.4%8.0%5.1%5.9%9.7%7.2%
Rev Chg 3Y Avg0.2%6.6%4.2%4.2%-10.8%12.1%4.2%
Rev Chg Q15.2%6.4%9.5%6.1%4.5%10.2%7.9%
QoQ Delta Rev Chg LTM3.6%1.6%2.3%1.5%1.4%2.5%1.9%
Op Mgn LTM14.0%15.2%9.2%15.0%2.7%-13.4%11.6%
Op Mgn 3Y Avg13.3%15.0%9.7%13.5%3.7%-16.3%11.5%
QoQ Delta Op Mgn LTM0.3%0.1%0.5%0.0%0.3%-0.7%0.2%
CFO/Rev LTM15.9%16.4%12.6%14.1%9.5%2.0%13.4%
CFO/Rev 3Y Avg14.6%15.4%12.1%15.1%10.1%-1.4%13.3%
FCF/Rev LTM11.6%10.0%9.4%9.8%4.2%-2.8%9.6%
FCF/Rev 3Y Avg10.1%8.4%8.6%10.5%5.0%-6.4%8.5%

Valuation

DGXHCALHDVASEMNEOMedian
NameQuest Di.HCA Heal.Labcorp DaVita Select M.NeoGenom. 
Mkt Cap20.598.223.19.41.61.214.9
P/S1.91.41.70.70.41.71.5
P/EBIT13.49.019.24.710.2-12.09.6
P/E21.516.530.211.311.9-11.514.2
P/CFO12.28.213.65.13.985.110.2
Total Yield6.3%6.8%4.4%8.9%11.4%-8.7%6.5%
Dividend Yield1.7%0.7%1.0%0.0%3.0%0.0%0.9%
FCF Yield 3Y Avg5.8%6.6%5.4%12.4%7.0%-2.3%6.2%
D/E0.30.50.31.41.80.30.4
Net D/E0.30.50.31.31.70.20.4

Returns

DGXHCALHDVASEMNEOMedian
NameQuest Di.HCA Heal.Labcorp DaVita Select M.NeoGenom. 
1M Rtn0.4%1.4%-0.5%-7.0%5.4%17.3%0.9%
3M Rtn9.0%8.1%11.0%-13.6%-11.2%30.1%8.6%
6M Rtn9.8%21.0%22.0%-17.9%-20.0%-3.9%2.9%
12M Rtn25.3%4.9%29.3%-23.0%-27.6%-31.0%-9.0%
3Y Rtn54.0%109.0%35.0%38.6%15.3%32.5%36.8%
1M Excs Rtn-0.7%0.3%-1.5%-8.0%4.4%16.3%-0.2%
3M Excs Rtn3.7%4.1%6.3%-18.4%-15.8%28.8%3.9%
6M Excs Rtn-11.6%-0.4%1.5%-44.4%-43.1%-23.9%-17.7%
12M Excs Rtn10.1%-7.7%14.9%-37.1%-42.5%-43.0%-22.4%
3Y Excs Rtn-23.7%31.3%-43.7%-38.4%-70.8%-74.5%-41.1%

Comparison Analyses

Title
0How Does Quest Diagnostics Stock Stack Up Against Its Peers?
1Quest Diagnostics vs. HCA: With Return Forecast Of 8.9%, Quest Diagnostics Is A Better Bet
2Why LH With 12% Upside May Beat DGX?
3Quest Diagnostics vs. DaVita HealthCare Partners: With Return Forecast Of 5%, Quest Diagnostics Is A Better Bet
4NEO Looks Stronger Than DGX With 32% Return Potential
5Quest Diagnostics vs. Genuine Parts: With Return Forecast Of 10%, Quest Diagnostics Is A Better Bet
6Quest Diagnostics vs. Jacobs Engineering Group: With Return Forecast Of 21%, Jacobs Engineering Group Is A Better Bet
7Quest Diagnostics vs. Monolithic Power Systems: With Return Forecast Of 47%, Monolithic Power Systems Is A Better Bet
8Quest Diagnostics vs. Marriot: With Return Forecast Of 24%, Marriot Is A Better Bet
9Quest Diagnostics vs. Vertex Pharmaceuticals: With Return Forecast Of 72%, Vertex Pharmaceuticals Is A Better Bet

Financials

$ Mil | FY: 12/312025Q22025Q12024Q42024Q32024Q22024Q12023Q42023Q32023Q22023Q12022Q42022Q3
Period End6/30/20253/31/202512/31/20249/30/20246/30/20243/31/202412/31/20239/30/20236/30/20233/31/202312/31/20229/30/2022
Filing Date7/23/20254/23/20252/20/202510/23/20247/24/20244/24/20242/22/202410/25/20237/27/20234/28/20232/21/202310/21/2022
Key Financials Quarterly            
Total Revenue2,7612,6522,6212,4882,3972,3662,2882,2952,3382,3312,3332,486
Ebitda596488506479478431392451468421261496
Operating Income438346361330355300267342348305135392
Net Income282220222226229194192225235202101256
EPS2.511.971.982.012.051.741.721.992.081.800.892.20
Key Financials TTM            
Total Revenue TTM10,52210,1589,8729,5399,3469,2879,2529,2979,4889,6039,88310,294
Ebitda TTM2,0691,9511,8941,7801,7521,7421,7321,6011,6461,6461,8202,205
Operating Income TTM1,4751,3921,3461,2521,2641,2571,2621,1301,1801,2201,4281,829
Net Income TTM9508978718418408468547637947939461,235
Growth Rates Quarterly            
Total Revenue Growth15.2%12.1%14.6%8.4%2.5%1.5%-1.9%-7.7%-4.7%-10.7%-15.0%-10.4%
EBITDA Growth24.7%13.2%29.1%6.2%2.1%2.4%50.2%-9.1%0.0%-29.2%-59.6%-37.5%
Operating Income Growth23.4%15.3%35.2%-3.5%2.0%-1.6%97.8%-12.8%-10.3%-40.5%-74.8%-39.9%
Net Income Growth23.1%13.4%15.6%0.4%-2.6%-4.0%90.1%-12.1%0.4%-43.1%-74.1%-49.3%
Margins Quarterly            
EBITDA Margin21.6%18.4%19.3%19.3%19.9%18.2%17.1%19.7%20.0%18.1%11.2%20.0%
Operating Income Margin15.9%13.0%13.8%13.3%14.8%12.7%11.7%14.9%14.9%13.1%5.8%15.8%
Net Income Margin10.2%8.3%8.5%9.1%9.6%8.2%8.4%9.8%10.1%8.7%4.3%10.3%
Cash & Debt            
Total Cash319188549764271474686143126175315700
Total Debt6,3846,5707,0876,9705,0885,3525,4984,9124,9594,6224,7144,640
Net Debt / (Cash)6,0656,3826,5386,2064,8174,8784,8124,7694,8334,4474,3993,940
Cash Flows Quarterly            
FCF from Operations54431446435636015452720744494334502
Cash Flows TTM            
FCF from Operations TTM1,6781,4941,3341,3971,2481,3321,2721,0791,3741,3321,7181,865
Returns to Shareholders Quarterly            
Dividends908484848479808080747578
Share Repurchases-0-0-0-0-0-0275-0-0-0461374
Return on Invested Capital (ROIC) Quarterly            
ROIC21.6%17.1%17.1%16.6%22.5%18.5%18.4%22.2%22.0%21.0%12.3%30.6%
Return on Invested Capital (ROIC) TTM            
ROIC TTM18.7%16.9%15.8%15.7%20.4%20.0%20.5%18.9%19.4%21.8%25.5%35.5%

Segment Financials

Revenue by Segment

$ Mil20242023202220212020
Diagnostic Information Services (DIS) Business8,9769,60910,4949,1397,405
Diagnostic Solutions (DS) group276274   
All other operating segments  294298321
Total9,2529,88310,7889,4377,726


Operating Income by Segment
$ Mil20242023202220212020
Diagnostic Information Services (DIS) Business1,5471,7042,6462,2011,298
Diagnostic Solutions (DS) group3420   
General corporate activities-319-296-294-269-109
All other operating segments  293942
Total1,2621,4282,3811,9711,231


Price Behavior

DGX Betas & Captures as of 9/30/2025

 1M2M3M6M1Y3Y
Beta0.61-0.27-0.280.310.280.34
Up Beta2.350.14-0.890.280.250.40
Down Beta1.69-0.81-0.760.310.300.24
Up Capture61%32%24%35%28%12%
Bmk +ve Days13233574144420
Stock +ve Days12253469136389
Down Capture-46%-123%-19%33%27%54%
Bmk -ve Days8192952107330
Stock -ve Days9173057114360

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

Short Interest

Short Interest: As Of Date9302025
Short Interest: Shares Quantity4,328,978
Short Interest: % Change Since 9152025-2.1%
Average Daily Volume757,427
Days-to-Cover Short Interest5.72
Basic Shares Quantity112,000,000
Short % of Basic Shares3.9%

Returns Analyses

Earnings Returns History

Expand for More

 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
7/22/20257.1%0.8%9.8%
4/22/20256.8%9.2%10.1%
1/30/20255.6%6.1%11.2%
10/22/20246.9%5.8%9.4%
7/23/2024-4.3%-3.5%2.4%
4/23/20245.1%7.2%10.2%
2/1/2024-1.0%-0.8%-2.9%
10/24/20231.8%6.6%10.6%
...
SUMMARY STATS   
# Positive141316
# Negative10118
Median Positive4.0%6.1%9.6%
Median Negative-3.0%-2.0%-6.2%
Max Positive7.1%18.5%20.6%
Max Negative-6.8%-11.6%-14.9%

SEC Filings

Expand for More

Report DateFiling DateFiling
6302025723202510-Q 6/30/2025
3312025423202510-Q 3/31/2025
12312024220202510-K 12/31/2024
93020241023202410-Q 9/30/2024
6302024724202410-Q 6/30/2024
3312024424202410-Q 3/31/2024
12312023222202410-K 12/31/2023
93020231025202310-Q 9/30/2023
6302023727202310-Q 6/30/2023
3312023428202310-Q 3/31/2023
12312022221202310-K 12/31/2022
93020221021202210-Q 9/30/2022
6302022722202210-Q 6/30/2022
3312022422202210-Q 3/31/2022
12312021228202210-K 12/31/2021
93020211022202110-Q 9/30/2021

Insider Activity

Expand for More

 OwnerTitleFiling DateActionPriceSharesTransacted
Value		Value of
Held Shares		Form
0Plewman PatrickSVP for Diagnostic Services8252025Sell185.001,975365,3752,824,765Form
1Plewman PatrickSVP for Diagnostic Services8192025Sell180.001,975355,5003,103,920Form
2DELANEY MARK ESVP & Chief Commercial Officer5142025Sell175.72874153,5791,471,128Form
3Davis J. E.CEO and President4042025Sell168.032,366397,55327,631,786Form
4KUPPUSAMY KARTHIKSVP, Clinical Solutions4042025Sell170.002,555434,3501,797,750Form

Industry Resources

External Quote Links


Prefer one of these to Trefis? Tell us why.